Chronic kidney disease-related atherosclerosis - proteomic studies of blood plasma

Proteome Science

Volumn 9, Issue , 2011, Pages

  Luczak, Magdalena ^a   Formanowicz, Dorota ^b   Pawliczak, Elzbieta ^b   Wanic Kossowska, Maria ^b   Wykretowicz, Andrzej ^b   Figlerowicz, Marek ^a,c  

^a INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c POZNAN UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 MICROGLOBULIN; APOLIPOPROTEIN A4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; HAPTOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

EID: 79955801373     PISSN: None     EISSN: 14775956     Source Type: Journal    
DOI: 10.1186/1477-5956-9-25     Document Type: Article

References (37)

1. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874. 10.1038/nature01323, 12490960.
2. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N, . European Uremic Toxin Work Group Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005, 20:1048-1056. 10.1093/ndt/gfh813, 15814534, European Uremic Toxin Work Group.
3. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J. Kidney disease as a risk factor from development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003, 108:2154-2169. 10.1161/01.CIR.0000095676.90936.80, 14581387.
4. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community based studies. J Am Soc Nephrol 2004, 15:1307-1315. 10.1097/01.ASN.0000123691.46138.E2, 15100371.
5. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004, 351:1285-1295. 10.1056/NEJMoa041365, 15385655.
6. Pelisek J, Assadian A, Sarkar O, Eckstein HH, Frank H. Carotid plaque composition in chronic kidney disease: a retrospective analysis of patients undergoing carotid endarterectomy. Eur J Vasc Endo Vasc Surg 2010, 39:11-16.
7. Kono K, Fujii H, Miyoshi N, Kawamori H, Shite J, Hirata K, Fukagawa M. Coronary plaque morphology using virtual histology-intravascular ultrasound analysis in hemodialysis patients. Ther Apher Dial
8. Guérin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000, 15:1014-1021. 10.1093/ndt/15.7.1014, 10862640.
9. Kraśniak A, Drożdż M, Pasowicz M, Chmiel G, Michałek M, Szumilak D, Podolec P, Klimeczek P, Konieczyńska M, Wicher-Muniak E, Tracz W, Khoa TN, Souberbielle JC, Drueke TB, Sulowicz W. Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patients. Nephrol Dial Transplant 2007, 22:515-521.
10. National Kidney Foundation (NKF) Kidney Disease Outcome Quality Initiative (K/DOQI) Advisory board K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002, 39:S1-246. National Kidney Foundation (NKF) Kidney Disease Outcome Quality Initiative (K/DOQI) Advisory board.
11. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
12. Candiano G, Bruschi M, Musante L, Santucci L, Ghiggeri GM, Carnemolla B, Orecchia P, Zardi L, Righetti PG. Blue Silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis 2004, 25:1327-1333. 10.1002/elps.200305844, 15174055.
13. Fach ME, Garulacan LA, Gao J, Xiao Q, Storm SM, Dubaquie YP, Hefta SA, Opiteck GJ. In vitro biomarker discovery for atherosclerosis by proteomics. Mol Cell Proteomics 2004, 3:1200-1210. 10.1074/mcp.M400160-MCP200, 15496433.
14. Berhane BT, Zong C, Liem DA, Huang A, Le S, Edmondson RD, Jones RC, Qiao X, Whitelegge JP, Ping P, Vondriska TM. Cardiovascular-related proteins identified in human plasma by the HUPO plasma proteome project pilot phase. Proteomics 2005, 5:3520-30. 10.1002/pmic.200401308, 16052623.
15. Grubb A. Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol 1992, 38:S20-7.
16. Corso A, Zappasodi P, Pascutto C, Bosoni T, Mangiacavalli S, Lorenzi A, Rusconi C, Lazzarino M. Urinary proteins in multiple myeloma: correlation with clinical parameters and diagnostic implication. Ann Hematol 2003, 82:487-91. 10.1007/s00277-003-0699-9, 12838370.
17. Herget-Rosenthal S, Poppen D, Husing J, Marggraf G, Pietruck F, Jakob HG, Philipp T, Kribben A. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin Chem 2004, 50:552-558. 10.1373/clinchem.2003.027763, 14709451.
18. Kusano E, Suzuki M, Asano Y, Itoh Y, Takagi K, Kawai T. Human alpha 1-microglobulin and its relationship to renal function. Nephron 1985, 41:320-324. 10.1159/000183608, 2415841.
19. Seishima M, Muto Y. An increased apo A-IV serum concentration of patients with chronic renal failure on hemodialysis. Clin Chim Acta 1987, 167:303-311. 10.1016/0009-8981(87)90350-0, 3621614.
20. Dieplinger H, Lobentanz EM, König P, Graf H, Sandholzer C, Matthys E, Rosseneu M, Utermann G. Plasma apolipoprotein A-IV metabolism in patients with chronic renal disease. Eur J Clin Invest 1992, 22:166-174. 10.1111/j.1365-2362.1992.tb01822.x, 1582441.
21. Kronenberg F, Kuen E, Ritz E, König P, Kraatz G, Lhotta K, Mann JF, Müller GA, Neyer U, Riegel W, Riegler P, Schwenger V, von Eckardstein A. Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure. J Am Soc Nephrol 2002, 13:461-469.
22. Boes E, Fliser D, Ritz E, König P, Lhotta K, Mann JF, Müller GA, Neyer U, Riegel W, Riegler P, Kronenberg F. Apolipoprotein A IV- predicts progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2006, 17:528-536. 10.1681/ASN.2005070733, 16382017.
23. Kronenberg F. Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol 2009, 5:677-689. 10.1038/nrneph.2009.173, 19935815.
24. Varghese SA, Powell TB, Budisavljevic MN, Oates JC, Raymond JR, Almeida JS, Arthur JM. Urine biomarkers predict the cause of glomerular disease. J Am Soc Nephrol 2007, 18:913-922. 10.1681/ASN.2006070767, 2733832, 17301191.
25. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003, 107:87-92. 10.1161/01.CIR.0000042700.48769.59, 12515748.
26. Emokpae MA, Uadia PO, Gadzama AA. Correlation of oxidative stress and inflammatory markers with the severity of sickle cell nephropathy. Ann Afr Med 2010, 9:141-146. 10.4103/1596-3519.68363, 20710104.
27. Farrel DH. Pathophysiologic roles of the fibrinogen gamma chain. Curr Opin Hematol 2004, 11:151-155. 10.1097/01.moh.0000131440.02397.a4, 15257013.
28. Scott EM, Ariens RA, Grant PJ. Genetic and environmental determinants of fibrin structure and function relevance to clinical disease. Arterioscler Thromb Vasc Biol 2004, 24:1558-1566. 10.1161/01.ATV.0000136649.83297.bf, 15217804.
29. Marchand A, Galen RS, Van Lente F. The predictive value of serum haptoglobin in hemolytic disease. JAMA 1980, 243:1909-1911. 10.1001/jama.243.19.1909, 7365971.
30. Sadrzadem SM, Bozorgmehr J. Haptoglobin phenotypes in health and disorders. Am J Clin Pathol 2004, 121(Suppl 1):S97-S104.
31. Ekström B, Peterson PA, Berggård I. A urinary and plasma alpha1-glycoprotein of low molecular weight: isolation and some properties. Biochem Biophys Res Commun 1975, 65:1427-1433. 10.1016/S0006-291X(75)80388-3, 79416.
32. Akerstrom B, Logdberg LE, Berggard I, Osmark P, Lindqvist A. Alpha(1)-microglobulin: a yellow-brown lipocalin. Biochim Biophys Acta 2000, 1482:172-184. 10.1016/S0167-4838(00)00157-6, 11058759.
33. Stein O, Stein Y, Lefevre M, Roheim PS. The role of apolipoprotein A-IV in reverse cholesterol transport studied with cultured cells and liposomes derived from another analog of phosphatidylcholine. Biochim Biophys Acta 1986, 878:7-13.
34. Steinmetz A, Barbaras R, Ghalim N, Clavey V, Fruchart JC, Ailhaud G. Human apolipoprotein A-IV binds to apolipoprotein A-I/A-II receptor sites and promotes cholesterol efflux from adipose cells. J Biol Chem 1990, 265:7859-7863.
35. Kronenberg F, Stühlinger M, Trenkwalder E, Geethanjali FS, Pachinger O, von Eckardstein A, Dieplinger H. Low apolipoprotein A-IV plasma concentration in men with coronary artery disease. J Am Coll Cardiol 2000, 36:751-757. 10.1016/S0735-1097(00)00775-0, 10987595.
36. Itoh Y, Enomoto H, Takagi K, Kawai T. Clinical usefulness of serum alpha 1-microglobulin as a sensitive indicator for renal insufficiency. Nephron 1983, 33:69-70. 10.1159/000182911, 6188070.
37. Weber MH, Verweibe R. Alpha 1-microglobulin (protein HC): features of a promising indicator of proximal tubular dysfunction. Eur J Clin Chem Clin Biochem 1992, 30:83-91.